1 Università Cattolica del Sacro Cuore, Roma, Italy.
2 Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
3 UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
aim of our review has been to give an appropriate idea of analogies and
differences between primitive MDS (p-MDS) and t-MDS throughout an
accurate reviewing of English peer-reviewed literature focusing on
clinical, cytogenetic, epigenetic, and somatic mutation features of
these two groups of diseases.
MDS Diagnosis and Risk Classification
|Table 2. Cytogenetic
abnormalities in 306 patients with t-MDS/t-AML (t-MDS 224, t-AML 82).
Balanced chromosomal translocations are very rare in t-MDS where
abnormalities of chromosomes 5 or/and 7 are prevalent. From Smith et
Al. Blood. 2003
|Figure 1. Differences between p-MDS and t-MDS concerning the proportion of various risk groups and the respective survivals. Ok et al. Leukemia, 2014.|
|Figure 2. Comparison of Overall Survival and time to AML of the same risk groups between p-MDS and t-MDS same risk groups. Kuendgen et al. Leukemia 2021.|
|Figure 3. Frequency of common cytogenetic abnomrmalities in p-MDS, subdivided into isolated, with 1 additional anomaly, and complex anomalies (From Haase et al.)|
|Table 3. t-MDS p-MDS. Zeidan et al. 2017: Proportions of the different karyotypes and risk groups of t-MDS versus p-MDS.|
|Figure 4. Patient characteristics in de novo vs therapy-related MDS (data from Kuendgen et al. Leukemia 2021).
Abnormalities of chromosome 5
Chromosome 7 abnormalities
Chromosome 17 abnormalities
|Figure 5. Mutational
profiles in myeloid neoplasms. Mutational profile of therapy-related
myelodysplastic syndromes (t-MDS) versus de novo MDS. Asterisk denotes
genes with a significant difference between t-MDS versus p-MDS. Ok et al.  Leukemia Res., 2015.